Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation

Tze‐Fan Chao; Chia‐Jen Liu; Yenn‐Jiang Lin; Shih‐Lin Chang; Li‐Wei Lo; Yu‐Feng Hu; Ta‐Chuan Tuan; Jo‐Nan Liao; Fa‐Po Chung; Tzeng‐Ji Chen; Professor Gregory Lip; Shih‐Ann Chen

doi:10.1161/circulationaha.117.031658

Abstract

1 min read

Among patients with AF ≥90 years of age, warfarin was associated with a lower risk of ischemic stroke and positive net clinical benefit. Compared with warfarin, NOACs were associated with a lower risk of ICH. Thus, OACs may still be considered as thromboprophylaxis for elderly patients, with NOACs being the more favorable choice.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2020

Oral anticoagulants in extremely high risk very elderly (&gt;90 years) patients with Atrial Fibrillation

Tze‐Fan Chao, Professor Gregory Lip, S.A Chen

Article2019

P4793Comparing the effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in the elderly Asian patients with atrial fibrillation

Tze‐Fan Chao, Jo‐Nan Liao, Professor Gregory Lip, S A Chen

Article2019

Oral Anticoagulation in Asian Patients With Atrial Fibrillation and a History of Intracranial Hemorrhage

So-Ryoung Lee, Eue-Keun Choi, Soonil Kwon, Jin‐Hyung Jung, Kyungdo Han, Myung‐Jin Cha, Seil Oh, Professor Gregory Lip

Article2017

Liver Cirrhosis in Patients With Atrial Fibrillation: Would Oral Anticoagulation Have a Net Clinical Benefit for Stroke Prevention?

Ling Kuo, Tze‐Fan Chao, Chia‐Jen Liu, Yenn‐Jiang Lin, Shih‐Lin Chang, Li‐Wei Lo, Yu‐Feng Hu, Ta‐Chuan Tuan, Jo‐Nan Liao, Fa‐Po Chung, Tzeng‐Ji Chen, Professor Gregory Lip, Shih‐Ann Chen

Article2021

Impacts of off-label dosing noacs on clinical outcomes in very elderly patients with atrial fibrillation

Tze‐Fan Chao, Yin Chan, Professor Gregory Lip, S.A Chen